← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $169B	2,204	-27	-1%	$152B
2	2 Amgen AMGN $238B	1,763	+13	+0.7%	$99.8B
3	3 Eli Lilly LLY $1.13T	1,368	+34	+3%	$71.2B
4	4 Becton Dickinson BDX $52.7B	1,285	+24	+2%	$59.9B
5	5 McKesson MCK $116B	904	+13	+1%	$23.9B
6	6 Conagra Brands CAG $6.84B	743	+33	+5%	$11.6B
7	7 Regeneron Pharmaceuticals REGN $82.5B	624	+4	+0.6%	$25.1B
8	8 Lamb Weston LW $7.51B	547	+19	+4%	$8.14B
9	9 Teva Pharmaceutical Industries Limited TEVA $48B	539	+32	+6%	$16.2B
10	10 Novo Nordisk NVO $174B	536	-17	-3%	$7.57B
11	11 AstraZeneca AZN $259B	531	+11	+2%	$14.4B
12	12 DaVita DVA $11.9B	479	-19	-4%	$10.5B
13	13 ResMed RMD $34B	465	+19	+4%	$9.58B
14	14 West Pharmaceutical WST $26.9B	323	0	0%	$6.86B
15	15 DELISTED CATALENT, INC. CTLT	262	-12	-4%	$5.63B
16	16 DELISTED WW International WW	261	+37	+17%	$6.18B
17	17 Medifast MED $136M	258	+33	+15%	$1.69B
18	18 Accendra Health ACH $21.9M	229	-13	-5%	$944M
19	19 Fresenius Medical Care FMS $11.8B	225	-8	-3%	$763M
20	20 Herbalife HLF $1.52B	223	+17	+8%	$7.46B
21	21 Opko Health OPK $1.13B	214	-13	-6%	$670M
22	22 Tootsie Roll Industries TR $2.9B	173	-3	-2%	$430M
23	ARNA 23 DELISTED Arena Pharmaceuticals Inc ARNA	165	-5	-3%	$1.75B
24	TWNK 24 DELISTED Hostess Brands, Inc. Class A Common Stock TWNK	152	+3	+2%	$1.52B
25	25 Madrigal Pharmaceuticals MDGL $10.6B	148	+48	+48%	$2.27B